Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, ...

DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...

Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...

DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes ...

Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

Dexcom CGM systems provide automatic blood glucose updates every five minutes. FreeStyle Libre sensors can last up to 15 days and no longer need frequent scanning for updates. Both Dexcom and ...

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...

Dexcom, the San Diego-based maker of continuous glucose monitors for diabetes patients and prediabetics, announced Wednesday that it is laying off around 350 workers, or 3% of its global workforce.

Ladies and gentlemen, welcome to the DexCom Second Quarter 2025 Earnings Release Conference Call. My name is Abby, and I'll be your conference operator today. [Operator Instructions] As a reminder, ...

This is a Class I recall where 56 serious injuries have been reported. If you use one of Dexcom's continuous glucose monitoring systems, here's what you need to know. Taylor Leamey wrote about all ...